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Abstract
Necrotizing Enterocolitis (NEC) is one of the most devastating gastrointestinal diseases in neonates, particularly
among preterm infants in whom surgical NEC is the leading cause of morbidity. NEC pathophysiology occurs in
the hyper-reactive milieu of the premature gut after bacterial colonization. The resultant activation of the TLR4
pathway appears to be a strongly contributing factor. Advancements in metagenomics may yield new clarity to
the relationship between the neonatal intestinal microbiome and the development of NEC. After a century without
effective directed treatments, microbiome manipulation offers a promising therapeutic target for the prevention
and treatment of this devastating disease.
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Background
Worldwide, sepsis is the third leading cause of neonatal
mortality (Hansen et al. 2017a). Necrotizing Enterocolitis
(NEC) is one of the most devastating gastrointestinal
diseases in neonates, particularly among preterm infants
in whom surgical NEC is the leading cause of morbidity
(Carter and Holditch-Davis 2008). NEC is characterized
by submucosal edema and hemorrhage, infiltration of the
intestinal wall by neutrophils, disruption of the intestinal
villus architecture, and in severe cases, full thickness
necrosis or intestinal wall perforation (Papillon et al. 2013).
Classic early clinical signs of the disease include abdominal
distension, feeding intolerance, and bloody stool in
infants around 1 week old. Abdominal radiographs
can demonstrate pneumatosis intestinalis and/or portal
venous gas (Neu and Walker 2011) (Fig. 1).
In North America, NEC occurs in about 7% of infants
born between 500 and 1500 g (Neu and Walker 2011)
which translates into an incidence of around 1.1 per
1000 live births (Papillon et al. 2013). NEC has a mortality rate of approximately 30 %; lower birth weight infants
and infants who require surgical treatment of NEC
experience a higher mortality rate than larger babies
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or infants in whom NEC can be managed medically
(McElroy 2014; Fitzgibbons et al. 2009; Abdullah
et al. 2010). Necrotizing enterocolitis costs the United
States health care system over one billion dollars per
year (McElroy 2014) with an average cost for surgical
NEC between 300,000 and 600,000 dollars per patient
(Stey et al. 2015). In addition to the immediate morbidity
and economic costs associated with NEC, the disease
results in long term sequel in around 25% of the time,
such as neurodevelopmental delays or short gut
syndrome (Neu and Walker 2011; Nino et al. 2016;
Wadhawan et al. 2014).

The neonatal immune system and
necrotizing enterocolitis
NEC is a disease that occurs predominately in premature
infants; the likelihood of developing NEC is inversely
proportional to birth weight and gestational age (Guthrie
et al. 2003). Interestingly, the onset of NEC appears to
be most related to post gestational age (corrected
postnatal age) as opposed to actual postnatal age. The
peak incidence of NEC seems to occur at approximately
31 weeks post conceptual age. This highlights the
relationship between host development and the development of necrotizing enterocolitis (Neu and Pammi 2017).
There are several key differences between the preterm
and the term neonate that contribute to the increased
propensity of preterm neonates to develop NEC. The
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Fig. 1 Clinical findings of Necrotizing Enterocolitis. a Abdominal distension and erythema frequently seen in an infant with necrotizing enterocolitis.
b Necrotic bowel found upon surgical exploration for necrotizing enterocolitis. c Abdominal radiograph demonstrating portal venous gas
and pneumatosis intestinalis

gastrointestinal tract of the preterm neonate demonstrates
decreased intestinal barrier function (Xing et al. 2017;
Moore et al. 2016), an impaired intestinal immune defense
system (Lu et al. 2014b), and an increased inflammatory
propensity (Ferretti et al. 2017; Nanthakumar et al. 2011).
Furthermore, the immune system of a preterm
neonate is less developed than a baby born at term.
In all neonates both the adaptive and the innate
components of the immune system are immature
owing to reduced physical barriers and impaired and
delayed function of most cell types (Camacho-Gonzalez
et al. 2013; Wynn et al. 2009). Compared to term
neonates, preterm infants have a stunted immune system
possessing a smaller quantity of monocytes and neutrophils. The quality of these cells is also impaired with a
reduced ability to kill pathogens. In addition, preterm
neonates’ ability to produce cytokines is lowered translating into limited T cell activation (Table 1) (Melville and
Moss 2013; Mussi-Pinhata and Rego 2005).
Table 1 Comparison of the Term and Premature Neonatal
Immune System
Term

Preterm

↓ Physical barriers

↓↓↓ Physical barriers

↑ Effectiveness of immune
cells to target pathogens

↓ Number of monocytes and neutrophils
↓ Overall ability to produce cytokines
↓ T cell activation
↓ Number of natural killer cells

↓ Bactericidal/permabilityincreasing protein

↓↓ Bactericidal/permability-increasing
protein
↓ Passive Immunity (level of IgG depends
on transplacental transfer and thus
increases with gestation age)

↑ indicates increased; ↓ indicates decreased

The development of necrotizing enterocolitis
Despite decades of investigation into the pathophysiology
of NEC, it still not well defined. The importance of
bacterial colonization in the development of NEC was
recognized decades ago by Santulli et al. (Santulli et al.
1975) Despite this no single causative agent has been
identified. As such, most theories on the pathogenesis of
NEC focus on not a specific pathogen but a generalized
microbial imbalance of intestinal flora called dysbiosis
(Elgin et al. 2016). One evolving school of thought is
that the disruption of normal neonatal intestinal bacterium, or microbiome, induces a proinflammatory state,
allowing bacterial translocation across intestinal epithelia (Patel and Denning 2015). In 2016 Nino et al.
eloquently proposed a “unifying hypothesis for the
development of NEC: that the intestine of the premature neonate exists in a hyper-reactive state relative to
the full-term intestine, which favors NEC development
upon colonization with an appropriate microbial milieu
in a patient with a permissive genetic background”
(Nino et al. 2016).

The neonatal microbiome
The microbiota of each individual is approximately
10–100 trillion microbial cells with the majority of
colonization occurring in the gastrointestinal tract
(Ursell et al. 2012). The ability to study these cells
has greatly expanded in the recent past. Previous
methods of evaluation were limited to culture-based
techniques with the unfortunate limitation that many
bacterial cells seen in feces cannot currently be
cultured in a laboratory. In recent years new initiatives such as the Human Microbiome Roadmap, made
possible by the development of high throughput
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molecular techniques to analyze microbial DNA and
RNA, have greatly expanded our knowledge of the
microbiome (Torrazza and Neu 2013). In a healthy
individual the intestinal microbiota is commensal and
plays an important role in the regulation of multiple
metabolic, immune, and inflammatory pathways
within the host (Torrazza and Neu 2013; Hooper and
Gordon 2001; Murgas Torrazza and Neu 2011; Round
and Mazmanian 2009). This commensal relationship
still needs to develop in the neonate, especially the
preterm neonate. Furthermore, the premature infant’s
underdeveloped immune system has limited ability to
defend against harmful bacteria and tolerate commensal
species of bacteria (Murgas Torrazza and Neu 2011).

The development of the neonatal microbiome
Normal term infants are first colonized by Streptococcus,
Staphyococcus, Escherichia coli, Lactobacillus, and
Enterobacter. As these species consume oxygen they
allow for the subsequent colonization of anaerobic
bacterial species, mainly Clostridia, Bifidobacterium, and
members of the Firmicutes phyla (Palmer et al. 2007;
Park et al. 2005). The intestinal microbiome in premature infants develops differently. Preterm infants are fed
enterally earlier than nature intended and frequently
receive fortified feeds. They have an immature immune
system and frequently have indwelling supportive
devices (Elgin et al. 2016). When the gut microbiome of
preterm infants was compared to the microbiome of
term infants it demonstrated higher levels of facultative
anaerobes and reduced levels of anaerobes such as
Bifidobacterium and Bacteroides (Arboleya et al. 2017).
In addition they have an increased amount of potentially
pathogenic bacteria such as Escherichia coli, Staphylococcus,
and Klebsiella (Table 2) (Schwiertz et al. 2003).
The development of the microbiome in the neonatal
gut occurs in two waves. The first wave is common to
both term and preterm infants and depends on the
mode of childbirth. The factors affecting the second
wave vary between term and preterm infants. In term
infants the second wave is influenced by type of feeding
– breast feeding or formula feeding. As described above,
Table 2 Comparison of the Microbiome of Term and Premature
Neonates
Term

Premature

Clostridia

↑facultative anaerobes

Bifidobacterium

↓Bifidobacterium

Other Firmicutes

↑Staphylococcus
↑Escherichia coli, Klebsiella and
other Enterobacteriacease
↓Bacteroidetes

↑ indicates increased; ↓ indicates decreased
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a breast fed infant’s microbiome is rich in Bifidobacteria
and Bacteriodes. In contrast, formula-fed infants remain
predominately colonized by Streptococci, Staphylococci
and Lactobacilli. Preterm infants’ microbiome is largely
characterized by high numbers of Clostridiaceae and
Enterobacteriaceae with low number of Bifidobacteria
and Bacteroidetes (Vongbhavit and Underwood 2016;
Arboleya et al. 2012). Overall, the single most important
factor in the establishment of the microbiome of
preterm infants appears to be the degree of prematurity
(La Rosa et al. 2014). Rosa et al. characterized the progression of bacterial colonization in neonates and found
that the microbiome developed in an orderly fashion
and that mode of delivery, antibiotics, diet, and gestational age of the infant all altered the pace of the
progression but not the sequence. They postulate that
gut bacterial communities have a nonrandom assembly
that is punctuated by microbial population abruptions.
They collected all stools (922 specimens) from 58
premature infants, none of which had serious intraabdominal pathology, weighing < 1500 g in a single
tertiary care center neonatal intensive care unit where
extensive protocols were in place to limit exposure
to microbes to the extent possible. They found that
Bacilli, Gammaproteobacteria, and Clostridia represented 91.7% of all bacterial sequences. Only two
infants produced stools where those three classes did
not predominate (La Rosa et al. 2014).

The impact of the microbiome on inflammation
and the role of toll-like receptors
The intestinal mucosa recognizes bacterial products
via pattern recognition receptor (PRRs), the most well
studied of which are Toll-Like Receptors (TLR). The
TLRs recognize microbial associated molecular patterns
(MAMPs) (Rhee 2011). Patterns of intestinal colonization
help to regulate TLR expression. As a result, abnormal
colonization patterns can trigger inappropriate responses.
MAMPs activate specific TLRs which lead to activation of
nuclear factor kappa-beta (NF-κβ) and its inflammatory
pathway and caspases. These in turn propagate apoptosis
and activate transcription genes and induce cytokines
(IL-1, IL-6, IL-8, TNF-α, INF-1) (Torrazza and Neu 2013).
Although many commensal bacterial do not express some
key virulence factors (Murgas Torrazza and Neu 2011)
both commensal and pathogenic intestinal microbes
contain MAMPS. Even normal flora can be proinflammatory if host conditions are abnormal. TLRs
must maintain a delicate balance between an appropriate
inflammatory response to pathogenic bacteria and homeostasis by supporting important intestinal functions
including cell growth and proliferation, cytoprotection,
antimicrobial peptide secretion, and regulation of barrier
function (Patel and Denning 2015).
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After birth, the neonatal gut receives its first large
scale challenge of MAMPs activating TLR (Lu et al.
2014a). In addition, the lipopolysaccharides from gramnegative bacteria activate TLR-4 (Neal et al. 2006). After
TLR-4 activation, the premature gut, compared to the
gut of a full-term neonate, is more likely to mount a
relatively increased cytokine-mediated inflammatory
response. Among the most prominent of cytokines is
interleukin-8 which increases neutrophil chemotaxis and
results in inflammation which can lead to tissue injury
and NEC (Markel et al. 2006; Sharma et al. 2007). Some
investigators believe that the premature neonate’s
propensity for an exaggerated inflammatory response is
due to a deficiency in the expression of inhibitors of
the NF-κβ pathway (Claud et al. 2004; Spehlmann
and Eckmann 2009). Unlike pathogenic bacteria, commensal
bacteria reside in the gut without triggering inflammation.
Commensal microbes help the gut tolerate the constant
stimulation occurring in the gastrointestinal tract by
preventing their recognition by TLRs or downregulating the NF-κβ pathway by blocking degradation of its
inhibitors. In addition, in the normal neonatal gut, the low
level stimulus of TLR4 by commensal bacteria is beneficial
in intestinal homeostasis (Neish 2004; Neish et al. 2000).

Toll-like-receptors, inflammation, and
necrotizing enterocolitis in the premature gut
Toll like receptor 4 (TLR4) plays a critical role in the
development of NEC – its activation leads to mucosal
injury and reduced epithelial repair. Furthermore, TLR4
is upregulated in the premature gut as compared to the
gut of the full term neonate (Sodhi et al. 2010; Hackam
et al. 2013). TLR4 has an important role in the regulation
of normal gut development in utero; levels of TLR4 expression typically fall throughout gestation (Gribar et al. 2009).
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As a result, TLR4 levels are high in preterm neonate.
When the gut is subsequently colonized with numerous gram negative bacteria, there are deleterious
consequences of exaggerated TLR4 signaling including
increased release of proinflammatory cytokines, increased enterocyte apoptosis, and impaired mucosal
healing. In addition, bacterial translocation through
the gut mucosa activate TLR4 on the endothelia of
the intestinal vasculature, resulting in reduction of
blood flow and development of intestinal ischemia
and necrosis (Nino et al. 2016). A 2017 study by Hui
et al. demonstrated increased pro-inflammatory cytokines and enhanced expression of TLR4 in resected
intestinal samples from 28 to 29 week old infants
with NEC (Hui et al. 2017).
In addition to increased TLR4 signaling there are
other factors that predispose the premature gut to the
development of NEC (Fig. 2). The premature gut
displays decreased digestion, decreased nutrient absorption (Reisinger et al. 2014) and impaired intestinal
motility (Ren et al. 2017). It also has a high baseline
level of cellular endoplasmic reticulum stress. This
increases the likelihood of apoptosis in the intestinal
epithelium. Furthermore, there are decreased physical
barriers in the premature gut, with a decreased
number of mucus-producing goblet cells (Deplancke
and Gaskins 2001), immature tight junctions (Anand
et al. 2007), and increased microvascular tone in the
intestinal mesentery (Watkins and Besner 2013).
Although outside of the scope of this review, in
addition to the TLR4 pathway, other pathways and cell
types are thought to be important in the development
of NEC including platelet-activating factor and macrophages (Caplan et al. 2005; Frost and Caplan 2013;
Furukawa et al. 1993; Rabinowitz et al. 2001; Maheshwari
et al. 2011; MohanKumar et al. 2016).

Fig. 2 Factors that Predispose the Immature Gut to Necrotizing Enterocolitis. Pictorial representation of factors contributing to the propensity of the
immature gut to develop necrotizing enterocolitis
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The microbiome in necrotizing enterocolitis
Several studies validate the notion that the microbiome
of the neonate with NEC is fundamentally different from
the microbiome of the neonate who is unaffected by
NEC. However, there are a range of organisms implicated in these studies, further highlighting the lack of a
single causative agent. Additionally, direct comparison
of these studies are difficult due to limitations in 16S
rRNA sequencing (speciation is dependent on the
quality and length of the sequence, challenging primer
design, and inability to distinguish between living and
dead bacteria) and heterogeneous populations studiedincluding a wide range of post gestational ages at which
NEC develops (Hosny 2017).
Despite these limitations studies investigating the
microbiome of a neonate with NEC have been informative. Among those studies, Wang et al. reported a study
of 20 preterm infants from a single institution, 10 suffering from NEC and 10 without the disease. These
patients included four twin pairs. Bacterial DNA from
fecal samples were obtained and underwent sequencing
of the 16S rRNA gene. All 20 infants had low levels of
diversity in the intestinal bacterial colonization but
patients with NEC had a significantly reduced level of
diversity compared to unaffected neonates. They had an
increase in the colonization of Gammaproteobacteria
with a decrease in other bacterial species (Wang et al.
2009). Mai et al. collected weekly stool samples from
infants with a gestation age < 32 weeks or a birth
weight ≤ 1250 g. They then used 16S rRNA sequencing
to compare the diversity of the microbiota and the
prevalence of specific bacteria in nine infants with NEC
and nine matched controls. Patients with NEC has an
increase in Proteobacteria and a decrease in Firmicutes
between 1 week and < 72 h prior to the detection of
clinical NEC (Mai et al. 2011).
Investigators have also searched for a microbial pattern
that appears prior to NEC onset. Morrow et al. analyzed
stool samples from infants < 29 weeks gestational age
and compared infants who developed NEC to matched
controls. Infants who developed NEC not only had lower
diversity in their microbiome but distinct patterns. In
postnatal days 4 to 9, infants who developed NEC were
dominated by members of the Firmicutes phylum.
During days 10 to 16, samples from the remaining NEC
cases were dominated by Proteobacteria. Interestingly,
infants with Firmicutes dysbiosis developed NEC earlier
than infants with Proteobacteria dysbiosis. All infants
with NEC lacked Propionibacterium and were preceded
by either Firmicutes or Proteobacteria dysbiosis. However,
it should be noted that 25% of controls had this phenotype
as well (Morrow et al. 2013). Multiple studies have shown
that Proteobacteria can be associated with an increased
incidence of NEC; a fact that has been validated in the
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2017 meta-analysis of 14 previous studies of intestinal
dysbiosis in preterm infants who subsequently developed
NEC by Pammi and et al. (Lu and Ni 2015; Gritz and
Bhandari 2015; Pammi et al. 2017).

Factors impacting the neonatal microbiome
Given the differences in the microbiota of infants with
NEC, we will now consider factors that predispose
premature infants to dysbiosis focusing on the degree
of prematurity, antibiotics, formula feeding, and acid
suppressing medications (Fig. 3) (Vongbhavit and
Underwood 2016). Other factors predisposing to
dysbiosis, but not yet convincingly demonstrated to
be associated with the development of NEC include
mode of delivery and environmental toxins (Madan
et al. 2012; Moya-Perez et al. 2017). Additionally, the
impact of the NICU environment on the premature
infants’ microbiome has not been fully established.
Studies have established the diversity in the surface
microbiota of various NICUs and demonstrated that
intensive cleaning is effective in reshaping but not
eliminating the microbiota (Underwood and Sohn 2017).
Prenatal development of the microbiome
PCR studies of amniotic fluid have estimated the prevalence
of microbial invasion of the amniotic cavity to be more than
30–50% higher than previously detected by culture based
methods (DiGiulio 2012). The placental basal plate
was found to have a microbiome of its own with
many commensal bacterial species including organisms
from the phyla Firmicutes, Tenericutes, Proteobacteria,
Bacteriodetes, and Fusobacteria (Aagaard et al. 2014). It is
unclear whether this colonization has any impact on the
neonatal GI tract but, given that the fetus swallows large
volumes of amniotic fluid during gestation, it is logical
that the fetal intestine would be exposed to amniotic fluid
microbes (Torrazza and Neu 2013). This notion is further
supported by the findings of low levels of microbial DNA
in first-pass meconium (Hansen et al. 2015; Nagpal et al.
2016). Jimenez et al. were able to isolate low numbers of
Enterococcus, Staphylococcus, and Streptococcus in the
umbilical blood from scheduled, elective cesarean
sections. In a later study they tested the meconium from
term infants prior to breast feeding and found similar
organisms: Enterococcus, Staphylococcus, and Escherichia
coli (Jimenez et al. 2008; Jimenez et al. 2005).
The impact of mode of delivery on
the microbiome
In the United States the caesarean section rate continues
to rise, reaching 33.1% in 2013 (Mistry et al. 2006).
Several studies have demonstrated a difference in the
microbiome of infants born via cesarean delivery compared
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Fig. 3 Factors Impacting the Neonatal Gut Microbiome. Factors contributing to the development of the neonatal microbiome include both prenatal
factors such as the maternal microbiome, the microbiome of the amniotic fluid, the degree of prematurity and the mode of delivery, and postnatal
exposures including antibiotics, diet, and acid suppressing medications

to vaginally delivered neonates. Infants born via the
vaginal canal are typically seeded with vaginal flora
including Lactobacillus and Prevotella. In contrast,
infants born via cesarean section are typically seeded
with skin flora (Biasucci et al. 2008). Infants born via
cesarean section display delayed onset of colonization
of Bifidobacterium and Bacteroides with increased
levels of colonization by the Enterobacteriaceae family
(Dogra et al. 2015). In 2011 Domingiuez-Bello et al.
used sequencing technology to demonstrate that the
gastrointestinal microbiota of infants born vaginally
were colonized with Lactobacillus, but infants born via
cesarean delivery were colonized by bacteria typically
found in skin and hospitals such as Staphylococcus
and Acinetobacter (Dominguez-Bello et al. 2011).
They later demonstrated that exposing neonates delivered via cesarean section to maternal vaginal fluids at
birth could redirect the microbiome, making it similar
to neonates delivered vaginally (Dominguez-Bello
et al. 2016). Large numbers of epidemiologic studies
have demonstrated compelling evidence suggesting a
link between cesarean delivery and increased risk of
obesity, asthma, allergies, immune deficiencies, and
other atopic disease (Thavagnanam et al. 2008; Pistiner
et al. 2008; Huh et al. 2012; Sevelsted et al. 2015). However, to date, a direct link between delivery by cesarean
and NEC has not been found. Prognostic studies indicate

that cesarean section is a risk factor for NEC but this is
likely correlated not causative (Samuels et al. 2017).

Dietary impact on the microbiome
Multiple studies over several decades have demonstrated
that enteral feeding with human milk as opposed to
formula decreases the incidence of NEC (Sullivan et al.
2010; Lucas and Cole 1990). Breast milk contains immunoglobulins, cytokines, lactoferrin, and growth factors
(Torrazza and Neu 2013). Breast milk also contains
glycoproteins that have been shown to decrease organ
injury and inflammation in sepsis in mouse models
(Hansen et al. 2017b). In addition human milk contains
human milk oligosaccharides (HMO) that stimulates
the growth of “healthy” bacteria- Bifidobacteria and
Bacteroides species both possess the proper enzymes
to digest HMOs and metabolize them for energy.
HMOs are the third most abundant ingredient in
breast milk (Elgin et al. 2016). HMOs may help to select
for beneficial microbes by providing them with substrates
for growth, allowing them to thrive. This may decrease
the ability of opportunistic pathogenic microbes to
gain a foothold in the neonatal gut (Elgin et al. 2016).
Furthermore, one way in which breast milk is thought
to be beneficial is downregulation of TLR4 signaling
(He et al. 2016; Good et al. 2015).
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In addition to helping shape the intestinal microbiome
by nutrient selection, breast milk has its own microbiome which evolves over time. Initially colostrum
contains Staphylococcus, Streptococcus, Lactobacillus
and Weissella but over time the microbes are more
consistent with maternal oral flora (Veillonella, Leptotrichia,
and Prevotella). Interestingly, while milk samples from
mothers who underwent elective cesarean sections
varied in bacterial composition from milk samples
from mothers who experienced vaginal delivery, the
microbiome in the breast milk of mothers who underwent
nonelective cesarean sections was similar to the microbiome of milk among mothers with vaginal deliveries. This
suggests that maternal stress and hormones influence
breast milk microbiome more directly than mode of
delivery (Cabrera-Rubio et al. 2012).
After birth, breast fed infants are first colonized
with aerobic or facultative anaerobic bacteria followed
by a bloom of anaerobic bacteria. Formula fed infants’
gastrointestinal microbiomes differ by having fewer
anaerobes and a plethora of gram negative bacteria
(Le Huerou-Luron et al. 2010) and have increased
levels of Enterobacteriaceae, Bacteroides, and Clostridium
in their stools compared to infants who receive breast
milk. The effect on breast versus formula feeding on
the levels of the Bifidobacterium species are less clear
with some studies finding significantly reduced amounts
in formula fed infants and other studies showing no
difference at all (Penders et al. 2005; Roger et al. 2010;
Tannock et al. 2013; Adlerberth and Wold 2009;
Bezirtzoglou et al. 2011).

Impact of antibiotics on the microbiome
Antibiotic exposure has a large impact on the neonatal
microbiome delaying the colonization of beneficial
bacteria and reducing the diversity of the intestinal
microbiome, both factors which are thought to predispose the neonate to NEC (Torrazza and Neu 2013).
Years of research and numerous studies have demonstrated that use of antibiotics may be associated with
development of NEC (Cotten et al. 2009; Abdel Ghany
and Ali 2012; Kuppala et al. 2011). Alexander et al.
demonstrated there was a direct correlation between
duration of antibiotics and risk of developing NEC
among infants without culture-proven sepsis (Alexander
et al. 2011). For more detailed review of the topic,
Esaiassen et al. published a meta-analysis in 2017
demonstrating the same: prolonged antibiotic exposure
in uninfected preterm infants is associated with an
increased risk of NEC and/or death (Esaiassen et al. 2017).
Impact of acid suppression on the microbiome
Acid suppression therapy has a known impact on the
preterm microbiome. Gupta et al. demonstrated that the
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use of H2 blockers in premature infants shifts the
microflora pattern towards Proteobacteria and limits
the diversity of the fecal microbiome. These alterations
may predispose an infant to NEC (Gupta et al. 2013).
Romaine et al. performed a retrospective cohort study
and found that the use of H2 blockers are associated
with increased risk of the combined outcome of death,
NEC, or sepsis in hospitalized very low birth weight
infants (Romaine et al. 2016).

Therapeutic alteration of the
neonatal microbiome
Given the link between dysbiosis and NEC, altering the
microbiome is a promising target for future therapies
(Vongbhavit and Underwood 2016). A 2014 Cochrane
review of randomized and quasi-randomized trials found
that enteral supplementation of probiotics prevents
severe NEC and all cause mortality in preterm infants
(Robinson 2014). In 2016 Denkel et al. found that
dual-strain probiotics reduced NEC and mortality in
preterm infants in a German NICU (Denkel et al. 2016).
However, the evidence regarding probiotics is difficult to
interpret. Although the meta-analyses of probiotics usage
have shown a beneficial effect, not all individual randomized control trials have demonstrated the same. Trials are
difficult to generalize as many use a different study design,
differing probiotics, and differing infant diets and feeding
times (Patel et al. 2017). The strain of probiotics used is
likely to be important. The PiPs trial did not demonstrate
any benefit with routine administration of Bifidobacterium
breve (Costeloe et al. 2016). Furthermore, there are
conflicting opinions regarding giving live bacteria to
particular vulnerable preterm neonates.
Future directions
Research over the last decade has demonstrated the
importance of the gut microbiome on human health and
disease. Microbiome alterations have been associated
with a vast array of diseases ranging from cardiovascular
disease to colorectal cancer, obesity, diabetes, and rheumatoid arthritis (Shreiner et al. 2015). Furthermore, microbiome manipulation has already proven beneficial in the
treatment of clostridium difficile infection (Brandt 2012)
and has demonstrated promising results in the treatment of
inflammatory bowel disease (Hansen and Sartor 2015) and
in experimental models of obesity (Jayasinghe et al. 2016).
The above review demonstrates the link between gut
dysbiosis and necrotizing enterocolitis. It is logical then,
that future prevention and treatment of the disease will also
include a component of microbiome manipulation.
There are three major options for an approach to
microbiome-based therapies: additive, subtractive, or
modulatory therapies. Additive therapy includes the
manipulation of the microbiome by supplementing the
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microbiome of the host with either specific strains of
organisms or groups of natural or engineered microorganisms. Subtractive therapy involves the removal
of specific deleterious members of the microbiome to
cure disease. Modulatory therapies involve administration of nonliving agents, called prebiotics, to modify
the composition or activity of the host microbiome
(Mimee et al. 2016).
Probiotics are discussed in detail above. However,
before probiotics can routinely be used in the prevention
of NEC, dose, strain, and timing of administration need
to be standardized. Probiotics might require regulatory
approval for use in the neonate before they can become
standard of care. In addition to commercially available
probiotics the development of genetically engineered
probiotics are underway, although this process is still in
its infancy. Bacterial cells could be altered to allow
recombinant expression of therapeutic biomolecules.
This would overcome issues with bioavailability and drug
inactivation with oral administration. Protein synthesis of
the therapeutics could be tied to conditions associated
with the disease (Mimee et al. 2016).
Quantitative metagenomics can be used to directly
map the human gut microbiome. In the future this could
be used for risk detection (Ehrlich 2016). Current efforts
are aimed at risk detection of chronic diseases, but given
the association between gut dysbiosis and necrotizing
enterocololitis, and the knowledge that certain bacterial
strains appear more frequently in patients who develop
NEC, this strategy could be applied to the disease in the
future. At risk preterm infants would be good targets for
microbiome analysis. Microbiome patterns thought to be
associated with an increased risk for the development of
necrotizing enterocolitis could then be ideal candidates
for microbiome alteration.

Conclusion
In summary, NEC is among the most common and
lethal gastrointestinal diseases that plague premature
infants and results in high short and long term morbidity and mortality. The pathogenesis of this complex
disease has been studied for decades but only recently
have advancements underscored the importance of the
intestinal microbiome. The intestinal microbiome can
have both a protective or a pathogenic role in preventing
or contributing to the development of NEC. Achieving a
healthy complement of commensal bacteria can help
protect the preterm infant from gut inflammation and
injury leading to necrotizing enterocolitis. Although
much work lies ahead in order to translate the lessons
learned in the laboratory to clinical practice, the
manipulation of the intestinal microbiome is a promising
strategy for the prevention of necrotizing enterocolitis.
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